{"id":1067941,"date":"2020-10-21T11:35:34","date_gmt":"2020-10-21T15:35:34","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/teneobio-announces-a-research-collaboration-and-license-agreement-with-arsenalbio\/"},"modified":"2024-08-18T11:41:10","modified_gmt":"2024-08-18T15:41:10","slug":"teneobio-announces-a-research-collaboration-and-license-agreement-with-arsenalbio","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/teneobio-announces-a-research-collaboration-and-license-agreement-with-arsenalbio.php","title":{"rendered":"Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio"},"content":{"rendered":"<p><![CDATA[NEWARK, Calif., Oct.  21, 2020  (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has entered into a research collaboration and commercial license agreement with ArsenalBio for the use of Teneobio\u2019s UniDabs\u00ae, single-domain, human heavy chain only antibodies in Chimeric Antigen Receptor (CAR) T-cell therapy.]]><\/p>\n<p>See original here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"http:\/\/www.globenewswire.com\/news-release\/2020\/10\/21\/2111794\/0\/en\/Teneobio-Announces-a-Research-Collaboration-and-License-Agreement-With-ArsenalBio.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio\">Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>See original here: Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/teneobio-announces-a-research-collaboration-and-license-agreement-with-arsenalbio.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1067941","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1067941"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1067941"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1067941\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1067941"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1067941"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1067941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}